Casdin Capital’s Fate Therapeutics FATE Stock Holding History

Casdin Capital’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,050,000	Closed	-$7.67M	–	38
2023 Q4	$7.67M	Hold	2,050,000	–	–	0.75%	25
2023 Q3	$4.35M	Hold	2,050,000	–	–	0.48%	27
2023 Q2	$9.76M	Hold	2,050,000	–	–	0.85%	25
2023 Q1	$11.7M	Hold	2,050,000	–	–	0.96%	26
2022 Q4	$20.7M	Hold	2,050,000	–	–	1.6%	18
2022 Q3	$45.9M	Sell	2,050,000 -50,000	-2%	-$1.44M	3.02%	11
2022 Q2	$52M	Sell	2,100,000 -1,300,000	-38%	-$35.9M	4.4%	8
2022 Q1	$132M	Hold	3,400,000	–	–	5.91%	4
2021 Q4	$199M	Hold	3,400,000	–	–	5.61%	3
2021 Q3	$202M	Hold	3,400,000	–	–	5.02%	5
2021 Q2	$295M	Hold	3,400,000	–	–	7.49%	3
2021 Q1	$280M	Buy	3,400,000 +350,000	+11%	+$33.5M	8.35%	3
2020 Q4	$277M	Hold	3,050,000	–	–	8.22%	3
2020 Q3	$122M	Hold	3,050,000	–	–	5.46%	5
2020 Q2	$105M	Buy	3,050,000 +500,000	+20%	+$14.9M	6.19%	3
2020 Q1	$56.6M	Hold	2,550,000	–	–	6.01%	4
2019 Q4	$49.9M	Hold	2,550,000	–	–	4.59%	10
2019 Q3	$39.6M	Hold	2,550,000	–	–	4.1%	11
2019 Q2	$51.8M	Hold	2,550,000	–	–	4.85%	7
2019 Q1	$44.8M	Hold	2,550,000	–	–	4.92%	7
2018 Q4	$32.7M	Hold	2,550,000	–	–	5.6%	7
2018 Q3	$41.5M	Sell	2,550,000 -50,000	-2%	-$591K	5.05%	7
2018 Q2	$29.5M	Hold	2,600,000	–	–	4.12%	9
2018 Q1	$25.4M	Hold	2,600,000	–	–	4.46%	11
2017 Q4	$15.9M	Buy	2,600,000 +2,050,000	+373%	+$9.15M	3.87%	12
2017 Q3	$2.18M	Hold	550,000	–	–	0.62%	25
2017 Q2	$1.78M	Buy	+550,000	New	+$2.11M	0.66%	32

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Casdin Capital's FATE Position: Q1 2024 in Review

Casdin Capital sold out of Fate Therapeutics (FATE) in Q1 2024, closing a stake of 2,050,000 shares — an estimated $7.67M sold.

Casdin Capital first reported a position in FATE in Q2 2017 and held it in 27 quarters. The position peaked at $295M in Q2 2021. 167 funds tracked by Wall St. Rank hold FATE as of Q1 2024.

Casdin Capital reported no remaining Fate Therapeutics position as of Q1 2024 after selling out during the quarter.
Casdin Capital sold 2,050,000 Fate Therapeutics shares in Q1 2024, an estimated $7.67M.
Casdin Capital first reported a position in Fate Therapeutics in Q2 2017 and held it in 27 quarters.
Casdin Capital's Fate Therapeutics position peaked at $295M in Q2 2021.
167 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2024.

Based on Casdin Capital's 13F filing for Q1 2024, filed 15 May 2024.